All Stories

  1. Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome
  2. Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study
  3. The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex
  4. Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis
  5. The diagnostic value of the central vein sign in radiologically isolated syndrome
  6. Elsevier - Best clinical paper: Underemployment, work hour reduction, and income loss: A global, multi-centered, cohort study of neuromyelitis optica
  7. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment
  8. Infliximab for vascular involvement in Behçet's syndrome
  9. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
  10. Application of diagnostic criteria for optic neuritis – Authors' reply
  11. Auto brewery syndrome from the perspective of the neurologist
  12. Ocrelizumab in pediatric multiple sclerosis
  13. Analysis of determinants of treatment change in adult paediatric-onset MS patients
  14. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
  15. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis
  16. Treatment of MOG antibody associated disorders: results of an international survey
  17. Co-existence of multiple sclerosis and anti-NMDA receptor encephalitis: A case report and review of literature
  18. ‘Is RLS a harbinger and consequence of MS?: Striking results of the ‘RELOMS-T’ study’
  19. Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event
  20. We should monitor our patients with wearable technology instead of neurological examination – No
  21. Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)
  22. The persistence versus interchangeability of migraine and tension-type headaches in a 5-year population-based validated survey
  23. Management of skin, mucosa and joint involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome
  24. An open/pilot trial of cognitive behavioral therapy in Turkish patients with refractory chronic migraine
  25. Nervous system involvement in Behçetʼs syndrome
  26. Hemodialysis-related headache and how to prevent it
  27. Age is a critical determinant in recovery from multiple sclerosis relapses
  28. Reduced inhibition in brainstem circuits in classical trigeminal neuralgia
  29. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations
  30. Characteristics of optic neuropathy in Behçet disease
  31. Chronic Migraine: Burden, Comorbidities and Treatment
  32. Behçet’s Syndrome and Nervous System Involvement
  33. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome
  34. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome
  35. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
  36. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey
  37. Anomalies Characteristic of Central Nervous System Demyelination
  38. Common Clinical and Imaging Conditions Misdiagnosed as Multiple Sclerosis
  39. Cervical spinal cord atrophy
  40. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
  41. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
  42. Sex Differences of Migraine: Results of a Nationwide Home-based Study in Turkey
  43. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation
  44. Neuro-Behçet’s Disease – Clinical Features, Diagnosis and Differential Diagnosis
  45. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine
  46. Radiologically isolated syndrome in children
  47. Behçet’s syndrome: providing integrated care
  48. Myelopathy in Behçet's disease: The Bagel Sign
  49. Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey
  50. Next generation sequencing analysis of patients with familial cervical artery dissection
  51. Deficient prepulse inhibition of blink reflex in migraine and its relation to allodynia
  52. Identification of 3 Novel Patients with CLCN2-Related Leukoencephalopathy due to CLCN2 Mutations
  53. Headache service quality: evaluation of quality indicators in 14 specialist-care centres
  54. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders
  55. Integrated multidisciplinary clinics
  56. Infliximab is a plausible alternative for neurologic complications of Behçet disease
  57. Characterization of Migraineurs Having Allodynia
  58. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
  59. Phenotypic features of chronic migraine
  60. The Effects of Dalfampridine on Hereditary Spastic Paraparesis
  61. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
  62. European headache federation consensus on technical investigation for primary headache disorders
  63. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey
  64. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
  65. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort
  66. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis
  67. Symptomatic therapy in multiple sclerosis: Big pharma should do more—YES
  68. Retinal nerve fiber layer structure abnormalities in patients with Neuro-Behcet's disease
  69. CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes
  70. Early CNS neurodegeneration in radiologically isolated syndrome
  71. Diagnosis and Treatment in Neurosarcoidosis
  72. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
  73. Population-based study of vestibular symptoms in migraineurs
  74. Case-Based Diagnosis and Management of Headache Disorders
  75. Understanding Multiple Sclerosis Better in 2014 – Environmental Factors, Remyelination, Diagnostic Techniques, Treatment Decisions and the Future Focus of Multiple Sclerosis Treatment
  76. The global burden of headache in children and adolescents – developing a questionnaire and methodology for a global study
  77. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation
  78. Gender influences headache characteristics with increasing age in migraine patients
  79. Relapses and disability accumulation in progressive multiple sclerosis
  80. Neuro-Behçet Disease and Autoinflammatory Disorders
  81. Moyamoya syndrome or Behçet's disease?
  82. Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis
  83. BAb and MxA as Functional Biomarkers in Routine Clinical Laboratories for the Determination of Anti-IFN-Beta Antibodies and Their Bioactivity Levels in Multiple Sclerosis Patients
  84. The impact of depression and ghrelin on body weight in migraineurs
  85. Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab
  86. Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
  87. Neuro-Behçet syndrome
  88. A Polysomnographic and Clinical Study of Sleep Disorders in Patients with Behçet and Neuro-Behçet Syndrome
  89. Clinical and Radiological Features in CADASIL and NOTCH3-Negative Patients: A Multicenter Study from Turkey
  90. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
  91. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
  92. Asymptomatic MS
  93. Management of lower urinary tract dysfunction in multiple sclerosis: A systematic review and Turkish consensus report
  94. Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready
  95. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
  96. Letter by Benbir et al Regarding Article, “The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Scale. A Screening Tool to Select Patients for NOTCH3 Gene Analysis”
  97. The radiologically isolated syndrome dilemma: just an incidental radiological finding or presymptomatic multiple sclerosis?
  98. Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women
  99. The prevalence of chronic and episodic migraine in children and adolescents
  100. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
  101. Reversible intracranial parenchymal changes in MRI after MCA aneurysm treatment with stent-assisted coiling technique; possible nickel allergy
  102. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study
  103. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort
  104. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis
  105. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults
  106. Chronic cerebrospinal venous insufficiency: does ultrasound really distinguish multiple sclerosis subjects from healthy controls?
  107. Clinical characteristics of pediatric-onset neuro-Behcet disease
  108. A patient with established primary progressive multiple sclerosis transitions to ‘secondary’ relapsing–remitting disease course following a fulminant demyelinating episode
  109. Evaluation of Parenchymal Neuro-Behçet Disease by Using Susceptibility-Weighted Imaging
  110. Behçet’s Disease
  111. Epidemiological-based childhood headache natural history study: After an interval of six years
  112. Neurofilament ELISA validation
  113. Prevalence Of Multiple Sclerosis In The Metropolitan Area Of Edirne City, Turkey
  114. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease
  115. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis
  116. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis
  117. A Comparative ID Migraine™ Screener Study in Ophthalmology, ENT and Neurology Out-Patient Clinics
  118. EULAR recommendations for the management of Behcet disease
  119. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
  120. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease
  121. Validity of the ID-Migraine screener in the workplace
  122. Immunotherapy for clinically isolated syndrome? Not necessarily...
  123. The Burden of Headache in Neurology Outpatient Clinics in Turkey
  124. The validation of ID migraine™ screener in neurology outpatient clinics in Turkey
  125. Fatigue and sleep disturbance in multiple sclerosis
  126. The R110C mutation in Notch3 causes variable clinical features in two Turkish families with CADASIL syndrome
  127. Economic impact of primary headaches in Turkey: a university hospital based study: part II
  128. The spectrum of multiple sclerosis and treatment decisions
  129. Headache in Behçet's Syndrome
  130. Prevalence and factors affecting headache in Turkish schoolchildren
  131. Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome
  132. Validity and Reliability of the Turkish Migraine Disability Assessment (MIDAS) Questionnaire
  133. Beh??et??s syndrome and the nervous system
  134. MRI Findings in Pediatric Neuro-Behçet's Disease
  135. Behçet's Syndrome
  136. Bone status in multiple sclerosis: beyond corticosteroids
  137. A whole genome screen for linkage in Turkish multiple sclerosis
  138. Arthritis during interferon beta-1b treatment in multiple sclerosis
  139. The Sensitivity and Specificity of the Case Definition Criteria in Mersin
  140. Hepatitis B vaccine related-myelitis?*
  141. Vasculitis of the nervous system
  142. Beh�et's disease: diagnostic and prognostic aspects of neurological involvement
  143. Corticosteroid therapy augments gastroduodenal permeability to sucrose
  144. Survival and predictors of disability in Turkish MS patients
  145. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome
  146. Optic neuritis: A population-based study in Olrnsted County, Minnesota
  147. Glioblastoma of the cerebellum. Computed tomographic and pathologic considerations